Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2029)	11/8/2007 1:34:27 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

ARWR Is trading above the $4 level in spite of the general market. bigcharts.marketwatch.com In an article by Jerry Adler on the Nov 12, Issue of NEWSWEEK, he mentions that Mark Davis decided in 1996 to try to improve the side effects of chemotherapy after he was told by his wife who had been diagnosed of having breast cancer:"If you guys at Caltech are so smart, why don't you invent something better?" Mark Davis is a professor of chemical engineering at Caltech, with a specialty in nanoparticles, he is not a physician or biochemist, but he saw a way to apply his expertise to the problem, combining cyclodextrin with camptothecin, using the polymer to release the camptothecin gradually & trying to minimize the effects on healthy tissues.He worked on his project for 10 years & came with Insert's IT-101, which reportedly on the PI trying to asses toxicology & safety parameters in vivo,worked better than any one had expected.<g> According to the anecdotal report, the first patient, a young man with Ca of the pancreas & estimated time of survival around 3 months, was still alive more than a year later.Good results were also reportedly seen on patients with Cas of lung & kidney which had life expectancy around 6 months. But the problem was that after some of the results were discussed on the TV documentary "Curious" he started to have too many calls from desperate people that wanted to join the study & he didn't have the resources to accommodate. (The PII for IT-101 that was started in May 2006 is expected to be completed next January.) clinicaltrials.gov Bernard